Modular Medical Appoints David Bosshard as Head of International Operations to Drive Global Expansion of Pivot Insulin Delivery System
ByAinvest
Monday, Oct 6, 2025 8:51 am ET1min read
MODD--
The appointment comes at a pivotal time as Modular Medical advances its next-generation Pivot insulin delivery system through the U.S. and CE Mark regulatory processes. The company aims to enhance accessibility for underserved diabetes patients worldwide by targeting the $3 billion adult "almost-pumpers" diabetes market [1].
Key highlights of Bosshard's expertise and strategic impact include his success in scaling the Omnipod and launching the YpsoPump with international users, aligning perfectly with Modular Medical's mission to make affordable, intuitive patch pumps accessible worldwide. The company is excited to harness his expertise in launching the Pivot product internationally, as it seeks to access high-growth markets outside the U.S. and evaluate each for direct and indirect distribution opportunities [1].
Modular Medical's mission is to revolutionize insulin delivery with affordable, easy-to-use solutions for the millions of "almost-pumpers" who avoid traditional pumps due to complexity and cost. The Pivot insulin delivery system is not currently cleared for sale by the FDA, but the company is working towards regulatory approvals to expand its market reach [1].
Modular Medical has appointed David Bosshard as Head of International Operations to drive global growth of its Pivot insulin delivery system. Bosshard has two decades of experience scaling tubeless insulin delivery systems across Europe and beyond, including launching Insulet's Omnipod and Ypsomed's YpsoPump. He will leverage his success to position the Company for international growth in the wearable diabetes technology sector, targeting the $3 billion adult "almost-pumpers" diabetes market.
Modular Medical, Inc. (NASDAQ: MODD) has appointed David Bosshard as Head of International Operations to spearhead the global growth of its Pivot insulin delivery system. With two decades of experience in scaling tubeless insulin delivery systems across Europe and beyond, Bosshard will leverage his success in launching Insulet's Omnipod and Ypsomed's YpsoPump to position the company for international growth in the wearable diabetes technology sector [1].The appointment comes at a pivotal time as Modular Medical advances its next-generation Pivot insulin delivery system through the U.S. and CE Mark regulatory processes. The company aims to enhance accessibility for underserved diabetes patients worldwide by targeting the $3 billion adult "almost-pumpers" diabetes market [1].
Key highlights of Bosshard's expertise and strategic impact include his success in scaling the Omnipod and launching the YpsoPump with international users, aligning perfectly with Modular Medical's mission to make affordable, intuitive patch pumps accessible worldwide. The company is excited to harness his expertise in launching the Pivot product internationally, as it seeks to access high-growth markets outside the U.S. and evaluate each for direct and indirect distribution opportunities [1].
Modular Medical's mission is to revolutionize insulin delivery with affordable, easy-to-use solutions for the millions of "almost-pumpers" who avoid traditional pumps due to complexity and cost. The Pivot insulin delivery system is not currently cleared for sale by the FDA, but the company is working towards regulatory approvals to expand its market reach [1].

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet